Total Payments
$3,132
2024 Payments
$39.57
Companies
26
Transactions
131
Medicare Patients
986
Medicare Billing
$109,363
Payment Breakdown by Category
Food & Beverage$3,039 (97.1%)
Education$92.34 (2.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,039 | 128 | 97.1% |
| Education | $92.34 | 3 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $556.77 | 24 | $0 (2022) |
| Allergan, Inc. | $361.92 | 24 | $0 (2021) |
| Celgene Corporation | $249.76 | 3 | $0 (2017) |
| LEO Pharma Inc. | $232.81 | 11 | $0 (2022) |
| Galderma Laboratories, L.P. | $229.65 | 11 | $0 (2021) |
| MAYNE PHARMA INC. | $224.82 | 12 | $0 (2021) |
| Almirall LLC | $183.75 | 3 | $0 (2021) |
| Janssen Biotech, Inc. | $177.52 | 8 | $0 (2024) |
| Merz North America, Inc. | $155.67 | 3 | $0 (2023) |
| Lilly USA, LLC | $154.77 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39.57 | 2 | Janssen Biotech, Inc. ($20.00) |
| 2023 | $167.19 | 4 | Merz North America, Inc. ($127.09) |
| 2022 | $261.83 | 12 | PFIZER INC. ($74.45) |
| 2021 | $656.85 | 28 | PFIZER INC. ($150.49) |
| 2020 | $457.12 | 23 | MAYNE PHARMA INC. ($121.87) |
| 2019 | $437.43 | 14 | Almirall LLC ($149.88) |
| 2018 | $460.27 | 21 | PFIZER INC. ($206.15) |
| 2017 | $651.37 | 27 | Celgene Corporation ($249.76) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: DERMATOLOGY | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 08/18/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.57 | General |
| Category: Dermatology | ||||||
| 08/15/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Immunology | ||||||
| 05/18/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $94.00 | General |
| Category: Musculoskeletal | ||||||
| 05/18/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: Musculoskeletal | ||||||
| 12/15/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: DERMATOLOGY | ||||||
| 11/23/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: DERMATOLOGY | ||||||
| 10/18/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: Inflammation | ||||||
| 09/29/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: DERMATOLOGY | ||||||
| 08/24/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $32.10 | General |
| Category: Immunology | ||||||
| 07/26/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Immunology | ||||||
| 06/20/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: Inflammation & Immunology | ||||||
| 04/27/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: Immunology | ||||||
| 03/29/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $26.75 | General |
| Category: Dermatology | ||||||
| 03/22/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Immunology | ||||||
| 02/22/2022 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: DERMATOLOGY | ||||||
| 02/17/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Inflammation & Immunology | ||||||
| 12/08/2021 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug), DUOBRII, ARAZLO | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Podiatry | ||||||
| 11/24/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: DERMATOLOGY | ||||||
| 10/05/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: DERMATOLOGY | ||||||
| 09/28/2021 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $22.53 | General |
| 09/22/2021 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $31.61 | General |
| Category: Immunology | ||||||
| 08/10/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $38.29 | General |
| Category: Immunology | ||||||
| 07/29/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 173 | 420 | $30,169 | $18,739 |
| 2022 | 7 | 224 | 433 | $33,008 | $21,078 |
| 2021 | 7 | 320 | 806 | $56,698 | $37,008 |
| 2020 | 7 | 269 | 752 | $48,581 | $32,539 |
Total Patients
986
Total Services
2,411
Medicare Billing
$109,363
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 68 | $9,677 | $6,260 | 64.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 25 | 37 | $4,914 | $3,668 | 74.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 50 | $5,450 | $3,470 | 63.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 24 | 40 | $3,600 | $1,663 | 46.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $2,362 | $1,459 | 61.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 13 | 14 | $1,682 | $1,113 | 66.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 21 | 192 | $2,486 | $1,106 | 44.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 81 | $8,593 | $5,762 | 67.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 56 | $8,190 | $5,450 | 66.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 35 | 35 | $4,256 | $2,588 | 60.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 23 | 28 | $3,630 | $2,525 | 69.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 25 | 28 | $3,262 | $2,245 | 68.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 25 | 36 | $3,240 | $1,524 | 47.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 22 | 169 | $1,838 | $983.20 | 53.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 143 | $14,356 | $10,035 | 69.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 105 | $15,143 | $10,002 | 66.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 33 | 47 | $5,863 | $4,357 | 74.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 49 | 49 | $5,731 | $3,821 | 66.7% |
| 17000 | Destruction of skin growth | Office | 2021 | 36 | 78 | $7,020 | $3,636 | 51.8% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 35 | 42 | $4,799 | $3,099 | 64.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 33 | 342 | $3,786 | $2,057 | 54.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 52 | 91 | $10,998 | $8,429 | 76.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 57 | 133 | $11,066 | $7,935 | 71.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 34 | 64 | $8,327 | $6,208 | 74.6% |
| 17000 | Destruction of skin growth | Office | 2020 | 36 | 74 | $6,840 | $3,314 | 48.5% |
About Dr. Lawrence Matt, M.D
Dr. Lawrence Matt, M.D is a Dermatopathology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1326166521.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Matt, M.D has received a total of $3,132 in payments from pharmaceutical and medical device companies, with $39.57 received in 2024. These payments were reported across 131 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($3,039).
As a Medicare-enrolled provider, Matt has provided services to 986 Medicare beneficiaries, totaling 2,411 services with total Medicare billing of $109,363. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Other Specialties Procedural Dermatology, Clinical & Laboratory Dermatological Immunology
- Location Los Angeles, CA
- Active Since 03/26/2007
- Last Updated 04/15/2024
- Taxonomy Code 207ND0900X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326166521
Products in Payments
- EUCRISA (Drug) $520.08
- Otezla (Drug) $278.43
- Seysara (Drug) $183.75
- TALTZ (Drug) $154.77
- ENSTILAR (Drug) $149.46
- REMICADE (Biological) $139.99
- Xeomin (Biological) $127.09
- DORYX (Drug) $103.83
- BOTOX COSMETIC (Biological) $90.70
- Cimzia (Drug) $81.11
- FABIOR (Drug) $78.78
- JUBLIA (Drug) $61.55
- DUPIXENT DUPILUMAB INJECTION (Biological) $60.89
- EPIDUO FORTE (Drug) $59.89
- ILUMYA (Biological) $59.21
- OPZELURA (Drug) $49.32
- TREMFYA (Drug) $37.53
- CIBINQO (Drug) $36.69
- PICATO (Drug) $34.86
- QBREXZA (Drug) $34.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatopathology Doctors in Los Angeles
Philip Scumpia, M.d, M.D
Dermatopathology — Payments: $4,689
Dermatopathology $4,689
Dr. Nima Amini, M.d, M.D
Dermatopathology — Payments: $304.87
Dermatopathology $304.87
Dr. Gene Kim, Md, MD
Dermatopathology — Payments: $187.29
Dermatopathology $187.29
Dr. Honggang Shen, M.d, M.D
Dermatopathology — Payments: $175.15
Dermatopathology $175.15
Lyndon Su, Md, MD
Dermatopathology — Payments: $135.12
Dermatopathology $135.12
Dr. Kittane Ranganath, Md, MD
Dermatopathology — Payments: $124.84
Dermatopathology $124.84